5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming

BACKGROUND: Epigenetic therapy through demethylation of 5-methylcytosine has been largely ineffective in treating lung cancer, most likely due to poor tissue distribution with oral or subcutaneous delivery of drugs such as 5-azacytidine (5AZA). An inhalable, stable dry powder formulation of 5AZA was...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Kuehl, Philip J., Tellez, Carmen S., Grimes, Marcie J., March, Thomas H., Tessema, Mathewos, Revelli, David A., Mallis, Larry M., Dye, Wendy W., Sniegowski, Tyler, Badenoch, Aaron, Burke, Michael, Dubose, Devon, Vodak, David T., Picchi, Maria A., Belinsky, Steven A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156464/
https://ncbi.nlm.nih.gov/pubmed/32103148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0765-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky